Assessing Bristol Myers Squibb (BMY) Valuation After Key Multiple Myeloma And Alpha Thalassemia Updates

Simply Wall St

Tue, February 24, 2026 at 2:07 PM GMT+9 2 min read

In this article:

BMY

+0.97%

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

Investor interest in Bristol-Myers Squibb (BMY) has picked up after a cluster of clinical and regulatory milestones, including FDA Breakthrough Therapy Designation and Priority Review for iberdomide in multiple myeloma, as well as strong Phase 2 data for Reblozyl in alpha-thalassemia.

See our latest analysis for Bristol-Myers Squibb.

The recent clinical wins and upbeat analyst commentary appear to be contributing to building momentum, with a 24.87% 90 day share price return and a 21.20% five year total shareholder return at a latest share price of $61.25.

If this kind of pipeline news has your attention, it may be a good time to look across the sector and see how other healthcare names compare. You can start with our 27 healthcare AI stocks.

With Bristol-Myers Squibb up 24.87% over 90 days and trading only about 1% below the average analyst price target, is the market still underestimating the pipeline, or already pricing in much of the potential future growth story?

Most Popular Narrative: 5.8% Undervalued

According to Evangelos, the most followed narrative sees Bristol-Myers Squibb’s fair value at $65.00, a touch above the recent $61.25 share price and close to where some investors frame upside potential in this setup.

Full-Year 2024 Highlights:

Read the complete narrative.

Curious how that mix of reported loss, lower earnings and fast growing newer drugs still supports a higher fair value? The narrative leans heavily on revenue trends, margin rebuild and future earnings power. If you want to see exactly how those moving parts are wired together in the model, the full breakdown is worth a closer look.

Result: Fair Value of $65.00 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, that fair value story could be challenged if the GAAP loss per share persists longer than expected, or if cost saving plans and growth portfolio revenues fall short.

Find out about the key risks to this Bristol-Myers Squibb narrative.

Next Steps

With mixed signals across earnings, growth and valuation sentiment, do not wait for the crowd to decide for you. Check the data, weigh the trade offs and see 4 key rewards and 3 important warning signs to understand both sides before you commit fresh capital.

繼續閱讀  

Looking for more investment ideas?

Do not stop your research with one stock. Broaden your watchlist using focused screeners that surface different types of opportunities other investors might miss.

Target dependable cash generators by reviewing companies in our 15 dividend fortresses that may appeal if you want income alongside potential capital growth.

Hunt for mispriced opportunities through the screener containing 23 high quality undiscovered gems, where you can spot quality names that are not yet widely followed.

Prioritize resilience by scanning the 80 resilient stocks with low risk scores to find businesses that score well on stability and risk metrics.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include BMY.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

條款 及 私隱政策

Privacy Dashboard

More Info